LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.
In this Pharmaceutical Executive video interview, LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials. Robinson also discusses the company's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to improve engagement, address operational barriers, and prioritize sites with diverse patient demographics. Takeda has also enhanced investigator diversity through multilingual toolkits and educational sessions, and aims to expand these efforts globally by adapting strategies to regional needs.
Pharmaceutical Executive: What are the long-term sustainability plans for these initiatives? How will Takeda ensure that diversity and inclusion remain a priority in its clinical trials moving forward?
LaShell Robinson: We talked a little bit about our US efforts, but we're also intending to expand globally and this trial is included with that. We're also making sure that, region by region, we're adapting the trial to what is best for that region and the perspective that each of those patient populations or communities may bring. We try to get to the community before they've thought of a clinical trial so that they're empowered with that information. Region by region, that may differ. I'm really looking forward to the learnings that we'll get as we're connecting in different areas of the world around clinical research, and how we can make it a reality to connect.
As we may see a change, we are committed to patients, or what I like to call, PTRB: patient, trust, reputation, business. That is our corporate philosophy and those are always our four priorities when we are looking at developing a treatment. When we think about the reflection of disease in our clinical trials and making sure that it accurately reflects the patient population, it really becomes about what's best for patients and making sure that we have the best scientific research to do that.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Amgen’s Imdelltra Demonstrates Significant Overall Survival Improvement in Small Cell Lung Cancer
April 16th 2025In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared to standard-of-care chemotherapy.